Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim.
作者信息
Donadieu Jean, Beaupain Blandine, Rety-Jacob Frédérique, Nove-Josserand Raphaelle
出版信息
Haematologica. 2009 Aug;94(8):1175-7. doi: 10.3324/haematol.2008.005330.
Abstract
摘要
相似文献
1
Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim.
Haematologica. 2009 Aug;94(8):1175-7. doi: 10.3324/haematol.2008.005330.
2
Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease.
Haematologica. 2010 Apr;95(4):684-5. doi: 10.3324/haematol.2009.018333. Epub 2010 Jan 6.
3
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8.
4
Pegfilgrastim.
Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012.
5
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Pharmacotherapy. 2003 Aug;23(8 Pt 2):15S-19S. doi: 10.1592/phco.23.9.15s.32889.
6
Pegfilgrastim.
Expert Opin Biol Ther. 2002 Dec;2(8):985-92. doi: 10.1517/14712598.2.8.985.
7
Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Curr Med Res Opin. 2011 Jan;27(1):79-86. doi: 10.1185/03007995.2010.536527. Epub 2010 Nov 22.
8
Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
J Pediatr Hematol Oncol. 2005 Aug;27(8):449-51. doi: 10.1097/01.mph.0000175711.73039.63.
9
Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
Expert Opin Biol Ther. 2005 Dec;5(12):1635-46. doi: 10.1517/14712598.5.12.1635.
10
Granulocyte colony-stimulating factor corrects the neutropenia associated with glycogen storage disease type Ib.
Leukemia. 1991 Apr;5(4):347-9.
引用本文的文献
1
Clinical and biochemical footprints of inherited metabolic diseases. XIII. Respiratory manifestations.
Mol Genet Metab. 2023 Nov;140(3):107655. doi: 10.1016/j.ymgme.2023.107655. Epub 2023 Jul 24.
2
Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia.
PLoS Comput Biol. 2019 Jan 7;15(1):e1006664. doi: 10.1371/journal.pcbi.1006664. eCollection 2019 Jan.
3
Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.
Bone Marrow Transplant. 2015 Apr;50(4):523-30. doi: 10.1038/bmt.2014.297. Epub 2015 Jan 12.
4
Respiratory manifestations in patients with inherited metabolic diseases.
Eur Respir Rev. 2013 Dec;22(130):437-53. doi: 10.1183/09059180.00008012.
5
Neutropenia in primary immunodeficiency.
Curr Opin Hematol. 2013 Jan;20(1):55-65. doi: 10.1097/MOH.0b013e32835aef1c.
6
Overdose of pegfilgrastim: case report.
Int J Clin Pharm. 2012 Oct;34(5):690-2. doi: 10.1007/s11096-012-9653-z. Epub 2012 Jul 21.
7
Glucose-6-phosphatase deficiency.
Orphanet J Rare Dis. 2011 May 20;6:27. doi: 10.1186/1750-1172-6-27.
8
Congenital neutropenia: diagnosis, molecular bases and patient management.
Orphanet J Rare Dis. 2011 May 19;6:26. doi: 10.1186/1750-1172-6-26.
9
Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease.
Haematologica. 2010 Apr;95(4):684-5. doi: 10.3324/haematol.2009.018333. Epub 2010 Jan 6.
本文引用的文献
1
The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report.
Support Cancer Ther. 2006 Jul 1;3(4):220-31. doi: 10.3816/SCT.2006.n.020.
2
Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor.
Skinmed. 2006 Mar-Apr;5(2):96-8. doi: 10.1111/j.1540-9740.2006.04575.x.
3
Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim.
Leuk Lymphoma. 2005 Oct;46(10):1523-6. doi: 10.1080/10428190500144615.
4
Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim.
J Am Acad Dermatol. 2005 May;52(5):901-5. doi: 10.1016/j.jaad.2004.12.028.
5
Filgrastim in patients with neutropenia: potential effects on quality of life.
Drugs. 2002;62 Suppl 1:65-78. doi: 10.2165/00003495-200262001-00005.
6
Severe pulmonary arterial hypertension in type 1 glycogen storage disease.
Eur J Pediatr. 2002 Oct;161 Suppl 1:S93-6. doi: 10.1007/s00431-002-1012-y. Epub 2002 Jul 31.
7
Renal carcinoma in a patient with glycogen storage disease Ib receiving long-term granulocyte colony-stimulating factor therapy.
J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):188-9. doi: 10.1097/00043426-200003000-00028.
8
Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications.
Leukemia. 1997 Apr;11(4):466-78. doi: 10.1038/sj.leu.2400607.
9
Impairment in gas exchange after granulocyte colony stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrome.
Chest. 1995 Jan;107(1):276-8. doi: 10.1378/chest.107.1.276.
10
Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases.
Nouv Rev Fr Hematol (1978). 1994;35(6):529-34.
Zotero 插件